JP2025506768A5 - - Google Patents

Info

Publication number
JP2025506768A5
JP2025506768A5 JP2024549592A JP2024549592A JP2025506768A5 JP 2025506768 A5 JP2025506768 A5 JP 2025506768A5 JP 2024549592 A JP2024549592 A JP 2024549592A JP 2024549592 A JP2024549592 A JP 2024549592A JP 2025506768 A5 JP2025506768 A5 JP 2025506768A5
Authority
JP
Japan
Prior art keywords
antibody
peptide linker
payload
linker
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024549592A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506768A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/054455 external-priority patent/WO2023161291A1/en
Publication of JP2025506768A publication Critical patent/JP2025506768A/ja
Publication of JP2025506768A5 publication Critical patent/JP2025506768A5/ja
Pending legal-status Critical Current

Links

JP2024549592A 2022-02-22 2023-02-22 2つ以上のペイロードを含むペプチドリンカー Pending JP2025506768A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22158100.2 2022-02-22
EP22158100 2022-02-22
PCT/EP2023/054455 WO2023161291A1 (en) 2022-02-22 2023-02-22 Peptide linkers comprising two or more payloads

Publications (2)

Publication Number Publication Date
JP2025506768A JP2025506768A (ja) 2025-03-13
JP2025506768A5 true JP2025506768A5 (enExample) 2026-03-02

Family

ID=80447107

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024549592A Pending JP2025506768A (ja) 2022-02-22 2023-02-22 2つ以上のペイロードを含むペプチドリンカー

Country Status (8)

Country Link
US (1) US20250082774A1 (enExample)
EP (1) EP4482529A1 (enExample)
JP (1) JP2025506768A (enExample)
KR (1) KR20240150807A (enExample)
CN (1) CN118742328A (enExample)
AU (1) AU2023223556A1 (enExample)
CA (1) CA3243937A1 (enExample)
WO (1) WO2023161291A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116390771A (zh) 2020-07-13 2023-07-04 瑞泽恩制药公司 与蛋白中的谷氨酰胺残基缀合的喜树碱类似物及其用途
WO2024138000A1 (en) * 2022-12-21 2024-06-27 Regeneron Pharmaceuticals, Inc. Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof
WO2025082990A1 (en) 2023-10-15 2025-04-24 Araris Biotech Ag Antibody-drug conjugates using two different types of topoisomerase i inhibitors
WO2026013234A1 (en) 2024-07-10 2026-01-15 Araris Biotech Ag Triple-payload antibody-drug conjugates (adcs)

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6660510B2 (en) 2001-12-17 2003-12-09 Food Industry Research And Development Transglutaminase gene of Streptoverticillium ladakanum and the transglutaminase encoded therefrom
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
AU2008215422B2 (en) 2007-02-15 2011-07-14 Ajinomoto Co., Inc. Transglutaminase having disulfide bond introduced therein
US20100087371A1 (en) 2007-02-22 2010-04-08 Sean Hu Transglutaminase Variants with Improved Specificity
WO2009072004A2 (en) 2007-09-26 2009-06-11 Gemin X Pharmaceuticals Canada, Inc. Compositions and methods for effecting nad+ levels using a nicotinamide phosphoribosyl transferase inhibitor
AU2010234335A1 (en) 2009-04-08 2011-10-13 Deutsches Krebsforschungszentrum Amatoxin-armed target-binding moieties for the treatment of cancer
ES2784829T3 (es) 2009-04-08 2020-10-01 Faulstich Heinz Dr Componentes de unión a la superficie de células terapéuticas provistos de amatoxina diseñados para terapia de tumores
AR082886A1 (es) 2010-09-03 2013-01-16 Forma Therapeutics Inc Compuestos y composiciones farmaceuticas que los contienen
ES2402254T3 (es) 2010-09-30 2013-04-30 Heidelberg Pharma Ag Conjugados de amatoxinas con ligadores mejorados
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
EP2497499A1 (en) 2011-03-10 2012-09-12 Heidelberg Pharma GmbH Amatoxin-conjugates with improved linkages
EP2793947B1 (en) 2011-12-23 2021-02-03 Innate Pharma Enzymatic conjugation of polypeptides
EP2774624A1 (en) 2013-03-04 2014-09-10 Heidelberg Pharma GmbH Amatoxin derivatives
WO2015015448A2 (en) 2013-07-31 2015-02-05 Rinat Neuroscience Corp. Engineered polypeptide conjugates
EP3055304A1 (en) 2013-10-09 2016-08-17 Eli Lilly and Company Novel pyridyloxyacetyl tetrahydroisoquinoline compounds useful as nampt inhibitors
WO2015191883A1 (en) 2014-06-12 2015-12-17 Dophen Biomedical Homogenous antibody drug conjugates via enzymatic methods
JP2018510864A (ja) 2015-03-10 2018-04-19 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company トランスグルタミナーゼによって結合可能な抗体およびそれによって製造される結合体
EP3069734A1 (en) 2015-03-17 2016-09-21 Exiris S.r.l. Cryptophycin-based antibody-drug conjugates with novel self-immolative linkers
ES2855998T3 (es) 2015-08-07 2021-09-27 Merck Patent Gmbh Etiqueta transglutamina para bioconjugación específica de sitio eficiente
TWI714661B (zh) 2015-11-05 2021-01-01 法商賽諾菲公司 新穎念珠藻素化合物及接合物、其製備與其治療用途
PT3440076T (pt) 2016-04-07 2022-07-29 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas úteis como modeladores de proteína
WO2018154517A1 (en) * 2017-02-24 2018-08-30 Philogen Spa Immunocytokine combination therapy
TN2019000303A1 (en) 2017-05-10 2021-05-07 Sanofi Sa Peptidic linkers and cryptophycin conjugates, useful in therapy, and their preparation
NZ762376A (en) 2017-09-19 2022-08-26 Scherrer Inst Paul Transglutaminase conjugation method and linker
WO2019096867A1 (en) * 2017-11-14 2019-05-23 Debiopharm Research & Manufacturing S.A. Ligand-drug-conjugates as substrates for selective cleavage by the exopeptidase activity of cathepsin b
CA3128571A1 (en) 2019-03-19 2020-09-24 Paul Scherrer Institut Transglutaminase conjugation method with a glycine based linker

Similar Documents

Publication Publication Date Title
JP2025506768A5 (enExample)
JP2024081670A (ja) トランスグルタミナーゼコンジュゲーション方法およびリンカー
AU2015274506C1 (en) Homogenous antibody drug conjugates via enzymatic methods
CN108101825B (zh) 用于抗体-药物偶联的双取代马来酰胺类连接子及其制备方法和用途
US11230610B2 (en) Bivalent antibodies masked by coiled coils
CA3016172A1 (en) Derivatives of amanita toxins and their conjugation to a cell binding molecule
KR20200138759A (ko) 인간화 항-전립선 특이적 막 항원(psma) 항체 약물 접합체
JP2024501894A5 (enExample)
KR20200088402A (ko) 카텝신 b의 엑소펩티다제 활성에 의한 선택적인 절단의 기질로서 리간드-약물-접합체
TWI909461B (zh) 抗體-藥物偶聯物靶向治療前列腺癌和其他腫瘤
JP2023546493A5 (enExample)
JP2020532523A (ja) 抗egfr抗体薬物コンジュゲート(adc)及びその使用
TW201836647A (zh) 抗-prlr抗體藥物軛合物(adc)及其用途
EP4633634A2 (en) Novel camptothecin derivatives and conjugates thereof
JP2024539989A5 (enExample)
KR20250137203A (ko) 항체 약물 접합체
JP7130243B2 (ja) 二重特異性抗体を用いた抗体薬物複合体プラットホーム
WO2024119049A1 (en) Compositions and methods for protein internalization
CN117642430A (zh) Her2纳米抗体及偶联物的制备方法和用途
JP2026512687A (ja) ヒト化l1cam抗体-薬物複合体
CN114569735A (zh) 一种连接基-药物偶联物、制备方法及应用
US12419964B2 (en) Antibody drug conjugate (ADC) targeting Nectin 4 and comprising an exatecan payload
WO2026062219A1 (en) Antibody-drug conjugates of vincristine, processes for preparing the same and uses thereof
CN120774988A (zh) 一种连接子、抗体药物偶联物及其制备方法
TW202608928A (zh) 多特異性抗體藥物偶聯物